New Top Exec Reshuffle To Steer OGT Down Dx Path

Oxford Gene Technology has appointed its former head of R&D, John Anson, as CEO and brought in a new head of regulatory affairs, Paul Kenny, as the company shifts resources to the molecular diagnostics market.

UK specialist in genomic analysis and next-generation sequencing specialist Oxford Gene Technology Ltd. has promoted John Anson, its former EVP of R&D who has been at the company since 2006, to the role of CEO.

Anson takes over from Mike Evans, who has led the firm since 2005 and spearheaded its transformation from a microarray licensing-led business model to a molecular genetics products business, including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from In Vitro Diagnostics

More from Diagnostics